Literature DB >> 31673885

Therapies to limit myocardial injury in animal models of myocarditis: a systematic review and meta-analysis.

Joshua A Silverblatt1, Oliver J Ziff2, Luke Dancy1, Allen Daniel1, Ben Carter3, Paul Scott4, Daniel M Sado1, Ajay Shah1, Daniel I Bromage5.   

Abstract

Current myocarditis guidelines do not advocate treatment to prevent myocardial injury and scar deposition in patients with myocarditis and normal left ventricular ejection fraction. We aimed to ascertain the utility of beta blockers, calcium channel blockers and antagonists of the renin-angiotensin system in ameliorating myocardial injury, scar formation and calcification in animal in vivo models of myocarditis. The project was prospectively registered with the PROSPERO database of systematic reviews (CRD42018089336). Primary outcomes (necrosis, fibrosis and calcification) were meta-analysed with random-effects modelling. 52 studies were systematically reviewed. Meta-analysis was performed compared with untreated controls. In each study, we identified all independent comparisons of treatment versus control groups. The pooled weighted mean difference (WMD) indicated treatment reduced necrosis by 16.9% (71 controlled analyses, 95% CI 13.2-20.7%; P < 0.001), however there was less evidence of an effect after accounting for publication bias. Treatment led to a 12.8% reduction in fibrosis (73 controlled analyses, 95% CI 7.6-18.0%; P < 0.001). After accounting for publication bias this was attenuated to 7.8% but remained significant. Treatment reduced calcification by 4.1% (28 controlled analyses, 95% CI 0.2-8.0%; P < 0.0395). We observed significant heterogeneity in effect size in all primary endpoints, which was predominantly driven by differences between drug categories. Beta blockers and angiotensin-converting enzyme (ACE) inhibitors were the only agents that were effective for both necrosis and fibrosis, while only ACE inhibitors had a significant effect on calcification. This study provides evidence for a role for ACE inhibitors and beta blockers to prevent myocardial injury and scar deposition in in vivo models of myocarditis. There is a need for further well-designed studies to assess the translational application of these treatments.

Entities:  

Keywords:  Calcification; Drug treatment; Fibrosis; Meta-analysis; Myocarditis; Necrosis; Remodelling; Systematic review

Mesh:

Substances:

Year:  2019        PMID: 31673885      PMCID: PMC6823299          DOI: 10.1007/s00395-019-0754-x

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  81 in total

1.  Carvedilol treatment ameliorates acute coxsackievirus B3-induced myocarditis associated with oxidative stress reduction.

Authors:  Yue-Chun Li; Li-Sha Ge; Peng-Lin Yang; Ji-Fei Tang; Jia-Feng Lin; Peng Chen; Xue-qiang Guan
Journal:  Eur J Pharmacol       Date:  2010-05-08       Impact factor: 4.432

2.  Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.

Authors:  George Suzuki; Hideaki Morita; Takayuki Mishima; Victor G Sharov; Anastassia Todor; Elaine J Tanhehco; Amy E Rudolph; Ellen G McMahon; Sidney Goldstein; Hani N Sabbah
Journal:  Circulation       Date:  2002-12-03       Impact factor: 29.690

3.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

4.  Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies.

Authors:  P Richardson; W McKenna; M Bristow; B Maisch; B Mautner; J O'Connell; E Olsen; G Thiene; J Goodwin; I Gyarfas; I Martin; P Nordet
Journal:  Circulation       Date:  1996-03-01       Impact factor: 29.690

5.  Tetrandrine reverses human cardiac myofibroblast activation and myocardial fibrosis.

Authors:  Guoqi Teng; Daniyil Svystonyuk; Holly E M Mewhort; Jeannine D Turnbull; Darrell D Belke; Henry J Duff; Paul W M Fedak
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-04-10       Impact factor: 4.733

6.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  BMJ       Date:  2009-07-21

7.  Oral administration of candesartan improves the survival of mice with viral myocarditis through modification of cardiac adiponectin expression.

Authors:  Seiichiro Saegusa; Yu Fei; Takashi Takahashi; Hiroyuki Sumino; Junji Moriya; Ken Kawaura; Jun-ichi Yamakawa; Tohoru Itoh; Shigeto Morimoto; Takeshi Nakahashi; Kunimitsu Iwai; Masayuki Matsumoto; Tsugiyasu Kanda
Journal:  Cardiovasc Drugs Ther       Date:  2007-06       Impact factor: 3.727

8.  Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis.

Authors:  Christoph Gräni; Christian Eichhorn; Loïc Bière; Venkatesh L Murthy; Vikram Agarwal; Kyoichi Kaneko; Sarah Cuddy; Ayaz Aghayev; Michael Steigner; Ron Blankstein; Michael Jerosch-Herold; Raymond Y Kwong
Journal:  J Am Coll Cardiol       Date:  2017-10-17       Impact factor: 24.094

9.  Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis.

Authors:  Li Yue-Chun; Zhang Teng; Zhou Na-Dan; Ge Li-Sha; Luo Qin; Guan Xue-Qiang; Lin Jia-Feng
Journal:  PLoS One       Date:  2012-06-28       Impact factor: 3.240

10.  Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction.

Authors:  Brian P Halliday; Ankur Gulati; Aamir Ali; Kaushik Guha; Simon Newsome; Monika Arzanauskaite; Vassilios S Vassiliou; Amrit Lota; Cemil Izgi; Upasana Tayal; Zohya Khalique; Colin Stirrat; Dominique Auger; Nilesh Pareek; Tevfik F Ismail; Stuart D Rosen; Ali Vazir; Francisco Alpendurada; John Gregson; Michael P Frenneaux; Martin R Cowie; John G F Cleland; Stuart A Cook; Dudley J Pennell; Sanjay K Prasad
Journal:  Circulation       Date:  2017-03-28       Impact factor: 29.690

View more
  7 in total

1.  Mammalian STE20-Like Kinase 2 Promotes Lipopolysaccharides-Mediated Cardiomyocyte Inflammation and Apoptosis by Enhancing Mitochondrial Fission.

Authors:  Yanan Tian; Haijiu Song; Wei Qin; Zhenjiang Ding; Ying Zhang; Weichao Shan; Dapeng Jin
Journal:  Front Physiol       Date:  2020-08-06       Impact factor: 4.755

2.  Resveratrol Improves Bnip3-Related Mitophagy and Attenuates High-Fat-Induced Endothelial Dysfunction.

Authors:  Chen Li; Ying Tan; Jiandi Wu; Qinghui Ma; Shuchang Bai; Zhangqing Xia; Xiaoliang Wan; Jianqiu Liang
Journal:  Front Cell Dev Biol       Date:  2020-08-14

3.  Total Glucosides of Peony Protect Cardiomyocytes against Oxidative Stress and Inflammation by Reversing Mitochondrial Dynamics and Bioenergetics.

Authors:  Mengmeng Wang; Qiang Li; Ying Zhang; Hao Liu
Journal:  Oxid Med Cell Longev       Date:  2020-11-25       Impact factor: 6.543

4.  High Glucose Attenuates Cardioprotective Effects of Glucagon-Like Peptide-1 Through Induction of Mitochondria Dysfunction via Inhibition of β-Arrestin-Signaling.

Authors:  Xietian Pan; Chengxiang Li; Haokao Gao
Journal:  Front Physiol       Date:  2021-05-13       Impact factor: 4.566

5.  What has preclinical systematic review ever done for us?

Authors:  Ash Allanna Mark Russell; Brad A Sutherland; Lila M Landowski; Malcolm Macleod; David W Howells
Journal:  BMJ Open Sci       Date:  2022-03-12

6.  Melatonin improves mitochondrial biogenesis through the AMPK/PGC1α pathway to attenuate ischemia/reperfusion-induced myocardial damage.

Authors:  Xueyan Qi; Jin Wang
Journal:  Aging (Albany NY)       Date:  2020-04-19       Impact factor: 5.682

7.  A DARPin targeting activated Mac-1 is a novel diagnostic tool and potential anti-inflammatory agent in myocarditis, sepsis and myocardial infarction.

Authors:  Patrick M Siegel; István Bojti; Karlheinz Peter; Philipp Diehl; Nicole Bassler; Jessica Holien; Ulrike Flierl; Xiaowei Wang; Philipp Waggershauser; Xavier Tonnar; Christopher Vedecnik; Constanze Lamprecht; Ivana Stankova; Tian Li; Thomas Helbing; Dennis Wolf; Nathaly Anto-Michel; Lucia Sol Mitre; Julia Ehrlich; Lukas Orlean; Ileana Bender; Anne Przewosnik; Maximilian Mauler; Laura Hollederer; Martin Moser; Christoph Bode; Michael W Parker
Journal:  Basic Res Cardiol       Date:  2021-03-15       Impact factor: 17.165

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.